Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial - Röllig, C; Serve, H; Hüttmann, A (Lancet Oncol, 2015)
et al.